Recent advances in nanomedicine targeting amino acid metabolism for anti-tumor therapy
Source abstract
Abstract
Abstract During tumor occurrence, development, and treatment, tumor cells undergo energy and metabolic reprogramming, resulting in specific amino acids shortages and the presence of amino acid metabolites accumulating in the surrounding environment, which contribute to drug-resistance and immune evasion. Consequently, regulation of amino acid metabolism is a crucial aspect of tumor therapy. However, many amino acid metabolic regulators exhibit limited accumulation at the tumor site, leading to low treatment efficacy and heightened side effects. For example, high doses (up to 1200 mg twice daily) are necessary for the oral administration of indolimod to counteract its poor aqueous solubility, rapid clearance from the bloodstream, and limited accumulation at the tumor site. Encapsulation of amino acid metabolized pharmaceuticals using nanoplatforms is an essential means to address application challenges. In this review, we will first introduce the impact of amino acid metabolism on tumor cells and immune cells. Secondly, it discusses the current research status and mechanism of nano-engineered medications that target amino acid metabolism in synergy with other therapeutic modalities to fight against tumors. Finally, we summarize the features of amino acid metabolic regulation studies to provide new strategies for the development of antitumor nanomedicines.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Amino Acid Enzymes and Metabolism · Nanoplatforms for cancer theranostics · Supramolecular Self-Assembly in Materials
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Weichselbaum RR, Liang H, Deng L, Fu YX (2017) Radiotherapy and immunotherapy: a beneficial liaison? Nat Rev Clin Oncol 14:365–379. https://doi.org/10.1038/nrclinonc.2016.21110.1038/nrclinonc.2016.211 ↗
2. Brahmer JR, Lee JS, Ciuleanu TE, Bernabe CR, Nishio M, Urban L, Audigier-Valette C, Lupinacci L, Sangha R, Pluzanski A, Burgers J, Mahave M, Ahmed S, Schoenfeld AJ, Paz-Ares LG, Reck M, Borghaei H, O’Byrne KJ, Gupta RG, Bushong J, Li L, Blum SI, Eccles LJ, Ramalingam SS (2023) Five-year survival outcomes with nivolumab plus ipilimumab versus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer in checkmate 227. J Clin Oncol 41:1200–1212. https://doi.org/10.1200/JCO.22.0150310.1200/JCO.22.01503 ↗
3. Wolchok JD, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, Cowey CL, Schadendorf D, Wagstaff J, Dummer R, Ferrucci PF, Smylie M, Butler MO, Hill A, Marquez-Rodas I, Haanen J, Guidoboni M, Maio M, Schoffski P, Carlino MS, Lebbe C, McArthur G, Ascierto PA, Daniels GA, Long GV, Bas T, Ritchings C, Larkin J, Hodi FS (2022) Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma. J Clin Oncol 40:127–137. https://doi.org/10.1200/JCO.21.0222910.1200/JCO.21.02229 ↗
4. Rohani N, Hao L, Alexis MS, Joughin BA, Krismer K, Moufarrej MN, Soltis AR, Lauffenburger DA, Yaffe MB, Burge CB, Bhatia SN, Gertler FB (2019) Acidification of tumor at stromal boundaries drives transcriptome alterations associated with aggressive phenotypes. Cancer Res 79:1952–1966. https://doi.org/10.1158/0008-5472.CAN-18-160410.1158/0008-5472.CAN-18-1604 ↗
5. Kumagai S, Koyama S, Itahashi K, Tanegashima T, Lin YT, Togashi Y, Kamada T, Irie T, Okumura G, Kono H, Ito D, Fujii R, Watanabe S, Sai A, Fukuoka S, Sugiyama E, Watanabe G, Owari T, Nishinakamura H, Sugiyama D, Maeda Y, Kawazoe A, Yukami H, Chida K, Ohara Y, Yoshida T, Shinno Y, Takeyasu Y, Shirasawa M, Nakama K, Aokage K, Suzuki J, Ishii G, Kuwata T, Sakamoto N, Kawazu M, Ueno T, Mori T, Yamazaki N, Tsuboi M, Yatabe Y, Kinoshita T, Doi T, Shitara K, Mano H, Nishikawa H (2022) Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments. Cancer Cell 40:201–218. https://doi.org/10.1016/j.ccell.2022.01.00110.1016/j.ccell.2022.01.001 ↗
6. Yang L, Chu Z, Liu M, Zou Q, Li J, Liu Q, Wang Y, Wang T, Xiang J, Wang B (2023) Amino acid metabolism in immune cells: essential regulators of the effector functions, and promising opportunities to enhance cancer immunotherapy. J Hematol Oncol 16:59. https://doi.org/10.1186/s13045-023-01453-110.1186/s13045-023-01453-1 ↗
7. Chen J, Cui L, Lu S, Xu S (2024) Amino acid metabolism in tumor biology and therapy. Cell Death Dis 15:42. https://doi.org/10.1038/s41419-024-06435-w10.1038/s41419-024-06435-w ↗
8. Zhang S, Zeng X, Ren M, Mao X, Qiao S (2017) Novel metabolic and physiological functions of branched chain amino acids: a review. J Anim Sci Biotechnol 8:10. https://doi.org/10.1186/s40104-016-0139-z10.1186/s40104-016-0139-z ↗
9. Kelly B, Pearce EL (2020) Amino assets: how amino acids support immunity. Cell Metab 32:154–175. https://doi.org/10.1016/j.cmet.2020.06.01010.1016/j.cmet.2020.06.010 ↗
10. Gu C, Mao X, Chen D, Yu B, Yang Q (2019) Isoleucine plays an important role for maintaining immune function. Curr Protein Pept Sci 20:644–651. https://doi.org/10.2174/138920372066619030516313510.2174/1389203720666190305163135 ↗
11. Pol J, Bloy N, Buque A, Eggermont A, Cremer I, Sautes-Fridman C, Galon J, Tartour E, Zitvogel L, Kroemer G, Galluzzi L (2015) Trial watch: peptide-based anticancer vaccines. OncoImmunology 4:e974411. https://doi.org/10.4161/2162402X.2014.97441110.4161/2162402X.2014.974411 ↗
12. Werfel TA, Elion DL, Rahman B, Hicks DJ, Sanchez V, Gonzales-Ericsson PI, Nixon MJ, James JL, Balko JM, Scherle PA, Koblish HK, Cook RS (2019) Treatment-Induced tumor cell apoptosis and secondary necrosis drive tumor progression in the residual tumor microenvironment through MerTK and IDO1. Cancer Res 79:171–182. https://doi.org/10.1158/0008-5472.CAN-18-110610.1158/0008-5472.CAN-18-1106 ↗
13. Carbotti G, Barisione G, Airoldi I, Mezzanzanica D, Bagnoli M, Ferrero S, Petretto A, Fabbi M, Ferrini S (2015) IL-27 induces the expression of IDO and PD-L1 in human cancer cells. Oncotarget 6:43267–43280. https://doi.org/10.18632/oncotarget.653010.18632/oncotarget.6530 ↗
14. Schmidt SV, Schultze JL (2014) New Insights into IDO biology in bacterial and viral infections. Front Immunol 5:384. https://doi.org/10.3389/fimmu.2014.0038410.3389/fimmu.2014.00384 ↗
15. Liu Y, Liang X, Yin X, Lv J, Tang K, Ma J, Ji T, Zhang H, Dong W, Jin X, Chen D, Li Y, Zhang S, Xie HQ, Zhao B, Zhao T, Lu J, Hu Z, Cao X, Qin FX, Huang B (2017) Blockade of IDO-kynurenine-AhR metabolic circuitry abrogates IFN-gamma-induced immunologic dormancy of tumor-repopulating cells. Nat Commun 8:15207. https://doi.org/10.1038/ncomms1520710.1038/ncomms15207 ↗
16. Wei L, Zhu S, Li M, Li F, Wei F, Liu J, Ren X (2018) High indoleamine 2,3-dioxygenase is correlated with microvessel density and worse prognosis in breast cancer. Front Immunol 9:724. https://doi.org/10.3389/fimmu.2018.0072410.3389/fimmu.2018.00724 ↗
17. Hornyak L, Dobos N, Koncz G, Karanyi Z, Pall D, Szabo Z, Halmos G, Szekvolgyi L (2018) The role of indoleamine-2,3-dioxygenase in cancer development, diagnostics, and therapy. Front Immunol 9:151. https://doi.org/10.3389/fimmu.2018.0015110.3389/fimmu.2018.00151 ↗
18. Sharma S, Agnihotri N, Kumar S (2022) Targeting fuel pocket of cancer cell metabolism: a focus on glutaminolysis. Biochem Pharmacol 198:114943. https://doi.org/10.1016/j.bcp.2022.11494310.1016/j.bcp.2022.114943 ↗
19. Mukha A, Kahya U, Dubrovska A (2021) Targeting glutamine metabolism and autophagy: the combination for prostate cancer radiosensitization. Autophagy 17:3879–3881. https://doi.org/10.1080/15548627.2021.196268210.1080/15548627.2021.1962682 ↗
20. Gao X, Sanderson SM, Dai Z, Reid MA, Cooper DE, Lu M, Richie JJ, Ciccarella A, Calcagnotto A, Mikhael PG, Mentch SJ, Liu J, Ables G, Kirsch DG, Hsu DS, Nichenametla SN, Locasale JW (2019) Dietary methionine influences therapy in mouse cancer models and alters human metabolism. Nature 572:397–401. https://doi.org/10.1038/s41586-019-1437-310.1038/s41586-019-1437-3 ↗
21. Hens JR, Sinha I, Perodin F, Cooper T, Sinha R, Plummer J, Perrone CE, Orentreich D (2016) Methionine-restricted diet inhibits growth of MCF10AT1-derived mammary tumors by increasing cell cycle inhibitors in athymic nude mice. BMC Cancer 16:349. https://doi.org/10.1186/s12885-016-2367-110.1186/s12885-016-2367-1 ↗
22. Mossmann D, Muller C, Park S, Ryback B, Colombi M, Ritter N, Weissenberger D, Dazert E, Coto-Llerena M, Nuciforo S, Blukacz L, Ercan C, Jimenez V, Piscuoglio S, Bosch F, Terracciano LM, Sauer U, Heim MH, Hall MN (2023) Arginine reprograms metabolism in liver cancer via RBM39. Cell 186:5068–5083. https://doi.org/10.1016/j.cell.2023.09.01110.1016/j.cell.2023.09.011 ↗
23. Iyer RK, Kim HK, Tsoa RW, Grody WW, Cederbaum SD (2002) Cloning and characterization of human agmatinase. Mol Genet Metab 75:209–218. https://doi.org/10.1006/mgme.2001.327710.1006/mgme.2001.3277 ↗
24. Geiger R, Rieckmann JC, Wolf T, Basso C, Feng Y, Fuhrer T, Kogadeeva M, Picotti P, Meissner F, Mann M, Zamboni N, Sallusto F, Lanzavecchia A (2016) L-Arginine Modulates T Cell Metabolism and Enhances Survival and Anti-tumor Activity. Cell 167:829–842. https://doi.org/10.1016/j.cell.2016.09.03110.1016/j.cell.2016.09.031 ↗
25. Zakharia Y, McWilliams RR, Rixe O, J. Drabick, Shaheen MF, Grossmann KF, Kolhe R, Pacholczyk R, Sadek R, Tennant LL, Smith CM, Kennedy EP, Link CJ., Vahanian NN, Yu J, Shen SS, Brincks EL, Rossi GR., Munn D, Milhem M (2021) Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients with advanced melanoma, J. Immunother. Cancer, p 9 . https://doi.org/10.1136/jitc-2020-00205710.1136/jitc-2020-002057 ↗
26. Feng Q, Bennett Z, Grichuk A, Pantoja R, Huang T, Faubert B, Huang G, Chen M, DeBerardinis RJ, Sumer BD, Gao J (2024) Severely polarized extracellular acidity around tumour cells. Nat Biomed Eng 8:787–799. https://doi.org/10.1038/s41551-024-01178-710.1038/s41551-024-01178-7 ↗
27. Jin M, Jin W (2020) The updated landscape of tumor microenvironment and drug repurposing. Signal Transduct Target Ther 5:166. https://doi.org/10.1038/s41392-020-00280-x10.1038/s41392-020-00280-x ↗
28. Du B, Jiao Q, Bai Y, Yu M, Pang M, Zhao M, Ma H, Yao H (2022) Glutamine metabolism-regulated nanoparticles to enhance chemoimmunotherapy by increasing antigen presentation efficiency. ACS Appl Mater Interfaces 14:8753–8765. https://doi.org/10.1021/acsami.1c2141710.1021/acsami.1c21417 ↗
29. Liu M, Yang M, Wan X, Tang Z, Jiang L, Wang S (2023) From nanoscopic to macroscopic materials by stimuli-responsive nanoparticle aggregation. Adv Mater 35:e2208995. https://doi.org/10.1002/adma.20220899510.1002/adma.202208995 ↗
30. Scaranti M, Cojocaru E, Banerjee S, Banerji U (2020) Exploiting the folate receptor alpha in oncology. Nat Rev Clin Oncol 17:349–359. https://doi.org/10.1038/s41571-020-0339-510.1038/s41571-020-0339-5 ↗
31. Santos E, Nogueira K, Fernandes L, Martins J, Reis A, Neto J, Junior I, Pessoa C, Petrilli R, Eloy JO (2021) EGFR targeting for cancer therapy: pharmacology and immunoconjugates with drugs and nanoparticles. Int J Pharm 592:120082. https://doi.org/10.1016/j.ijpharm.2020.12008210.1016/j.ijpharm.2020.120082 ↗
32. Wang X, Ding B, Liu W, Qi L, Li J, Zheng X, Song Y, Li Q, Wu J, Zhang M, Chen H, Wang Y, Li Y, Sun B, Ma P (2024) Dual starvations induce pyroptosis for orthotopic pancreatic cancer therapy through simultaneous deprivation of glucose and glutamine. J Am Chem Soc 146:17854–17865. https://doi.org/10.1021/jacs.4c0347810.1021/jacs.4c03478 ↗
33. Zeng Z, Zhang C, Li J, Cui D, Jiang Y, Pu K (2021) Activatable polymer nanoenzymes for photodynamic immunometabolic cancer therapy. Adv Mater 33:e2007247. https://doi.org/10.1002/adma.20200724710.1002/adma.202007247 ↗
34. Shi D, Wu X, Jian Y, Wang J, Huang C, Mo S, Li Y, Li F, Zhang C, Zhang D, Zhang H, Huang H, Chen X, Wang YA, Lin C, Liu G, Song L, Liao W (2022) USP14 promotes tryptophan metabolism and immune suppression by stabilizing IDO1 in colorectal cancer. Nat Commun 13:5644. https://doi.org/10.1038/s41467-022-33285-x10.1038/s41467-022-33285-x ↗
35. Klysz D, Tai X, Robert PA, Craveiro M, Cretenet G, Oburoglu L, Mongellaz C, Floess S, Fritz V, Matias MI, Yong C, Surh N, Marie JC, Huehn J, Zimmermann V, Kinet S, Dardalhon V, Taylor N (2015) Glutamine-dependent alpha-ketoglutarate production regulates the balance between T helper 1 cell and regulatory T cell generation. Sci Signal 8:ra97. https://doi.org/10.1126/scisignal.aab261010.1126/scisignal.aab2610 ↗
36. Nabe S, Yamada T, Suzuki J, Toriyama K, Yasuoka T, Kuwahara M, Shiraishi A, Takenaka K, Yasukawa M, Yamashita M (2018) Reinforce the antitumor activity of CD8(+) T cells via glutamine restriction. Cancer Sci 109:3737–3750. https://doi.org/10.1111/cas.1382710.1111/cas.13827 ↗
37. Oh MH, Sun IH, Zhao L, Leone RD, Sun IM, Xu W, Collins SL, Tam AJ, Blosser RL, Patel CH, Englert JM, Arwood ML, Wen J, Chan-Li Y, Tenora L, Majer P, Rais R, Slusher BS, Horton MR, Powell JD (2020) Targeting glutamine metabolism enhances tumor-specific immunity by modulating suppressive myeloid cells. J Clin Invest 130:3865–3884. https://doi.org/10.1172/JCI13185910.1172/JCI131859 ↗
38. Leone RD, Zhao L, Englert JM, Sun IM, Oh MH, Sun IH, Arwood ML, Bettencourt IA, Patel CH, Wen J, Tam A, Blosser RL, Prchalova E, Alt J, Rais R, Slusher BS, Powell JD (2019) Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasion. Science 366:1013–1021. https://doi.org/10.1126/science.aav258810.1126/science.aav2588 ↗
39. Wegiel B, Vuerich M, Daneshmandi S, Seth P (2018) Metabolic switch in the tumor microenvironment determines immune responses to anti-cancer therapy. Front Oncol 8:284. https://doi.org/10.3389/fonc.2018.0028410.3389/fonc.2018.00284 ↗
40. Chen S, Xu Y, Zhuo W, Zhang L (2024) The emerging role of lactate in tumor microenvironment and its clinical relevance. Cancer Lett 590:216837. https://doi.org/10.1016/j.canlet.2024.21683710.1016/j.canlet.2024.216837 ↗
41. Zhou X, Zhao W, Wang M, Zhang S, Li Y, Hu W, Ren L, Luo S, Chen Z (2020) Dual-modal therapeutic role of the lactate oxidase-embedded hierarchical porous zeolitic imidazolate framework as a nanocatalyst for effective tumor suppression. ACS Appl Mater Interfaces 12:32278–32288. https://doi.org/10.1021/acsami.0c0578310.1021/acsami.0c05783 ↗
42. Feng Q, Hao Y, Yang S, Yuan X, Chen J, Mei Y, Liu L, Chang J, Zhang Z, Wang L (2023) A metabolic intervention strategy to break evolutionary adaptability of tumor for reinforced immunotherapy. Acta Pharm Sin B 13:775–786. https://doi.org/10.1016/j.apsb.2022.10.02110.1016/j.apsb.2022.10.021 ↗
43. Ti D, Yan X, Wei J, Wu Z, Wang Y, Han W (2022) Inducing immunogenic cell death in immuno-oncological therapies. Chin J Cancer Res 34:1–10. https://doi.org/10.21147/j.issn.1000-9604.2022.01.0110.21147/j.issn.1000-9604.2022.01.01 ↗
44. Wang C, Ma C, Gong L, Guo Y, Fu K, Zhang Y, Zhou H, Li Y (2021) Macrophage polarization and its role in liver disease. Front Immunol 12:803037. https://doi.org/10.3389/fimmu.2021.80303710.3389/fimmu.2021.803037 ↗
45. Ren J, Zhou J, Liu H, Jiao X, Cao Y, Xu Z, Kang Y, Xue P (2021) Ultrasound (US)-activated redox dyshomeostasis therapy reinforced by immunogenic cell death (ICD) through a mitochondrial targeting liposomal nanosystem. Theranostics 11:9470–9491. https://doi.org/10.7150/thno.6298410.7150/thno.62984 ↗
46. Li Z, Li X, Lu Y, Zhu X, Zheng W, Chen K, Liu S, Wu J, Guan W (2024) Improved photodynamic therapy based on glutaminase blockage via tumor membrane coated CB-839/IR-780 nanoparticles. Small 20:e2305174. https://doi.org/10.1002/smll.20230517410.1002/smll.202305174 ↗
47. Chen G, Xu Q, Feng Z, Xu Q, Zhang X, Yang Y, Zhang Y, Liang XJ, Yu Z, Yu M (2022) Glutamine antagonist synergizes with electrodynamic therapy to induce tumor regression and systemic antitumor immunity. ACS Nano 16:951–962. https://doi.org/10.1021/acsnano.1c0854410.1021/acsnano.1c08544 ↗
48. Jian H, Zhang Y, Wang J, Chen Z, Wen T (2022) Zeolitic imidazolate framework-based nanoparticles for the cascade enhancement of cancer chemodynamic therapy by targeting glutamine metabolism. Nanoscale 14:8727–8743. https://doi.org/10.1039/d2nr01736a10.1039/d2nr01736a ↗
49. Wu F, Du Y, Yang J, Shao B, Mi Z, Yao Y, Cui Y, He F, Zhang Y, Yang P (2022) Peroxidase-like active nanomedicine with dual glutathione depletion property to restore oxaliplatin chemosensitivity and promote programmed cell death. ACS Nano 16:3647–3663. https://doi.org/10.1021/acsnano.1c0677710.1021/acsnano.1c06777 ↗
50. Brin E, Wu K, Lu HT, He Y, Dai Z, He W (2017) PEGylated arginine deiminase can modulate tumor immune microenvironment by affecting immune checkpoint expression, decreasing regulatory T cell accumulation and inducing tumor T cell infiltration. Oncotarget 8:58948–58963. https://doi.org/10.18632/oncotarget.1956410.18632/oncotarget.19564 ↗
51. Yeh TH, Chen YR, Chen SY, Shen WC, Ann DK, Zaro JL, Shen LJ (2016) Selective intracellular delivery of recombinant arginine deiminase (ADI) using pH-sensitive cell penetrating peptides to overcome ADI resistance in hypoxic breast cancer cells. Mol Pharm 13:262–271. https://doi.org/10.1021/acs.molpharmaceut.5b0070610.1021/acs.molpharmaceut.5b00706 ↗
52. Zang J, Yang Y, Zheng X, Yang Y, Zhao Y, Miao Z, Zhang T, Gu J, Liu Y, Yin W, Ma X, Ding Q, Dong H, Li Y, Li Y (2023) Dynamic tagging to drive arginine nano-assembly to metabolically potentiate immune checkpoint blockade therapy. Biomaterials 292:121938. https://doi.org/10.1016/j.biomaterials.2022.12193810.1016/j.biomaterials.2022.121938 ↗
53. Wu X, Cheng Y, Zheng R, Xu K, Yan J, Song P, Wang Y, Rauf A, Pan Y, Zhang H (2021) Immunomodulation of tumor microenvironment by Arginine-Loaded Iron Oxide Nanoparticles for Gaseous Immunotherapy. ACS Appl Mater Interfaces 13:19825–19835. https://doi.org/10.1021/acsami.1c0463810.1021/acsami.1c04638 ↗
54. Zhang J, Wang S, Guo X, Lu Y, Liu X, Jiang M, Li X, Qin B, Luo Z, Liu H, Li Q, Du YZ, Luo L, You J (2022) Arginine supplementation targeting tumor-killing immune cells reconstructs the tumor microenvironment and enhances the antitumor immune response. ACS Nano 16:12964–12978. https://doi.org/10.1021/acsnano.2c0540810.1021/acsnano.2c05408 ↗
55. Marquet J, Lasoudris F, Cousin C, Puiffe ML, Martin-Garcia N, Baud V, Chereau F, Farcet JP, Molinier-Frenkel V, Castellano F (2010) Dichotomy between factors inducing the immunosuppressive enzyme IL-4-induced gene 1 (IL4I1) in B lymphocytes and mononuclear phagocytes. Eur J Immunol 40:2557–2568. https://doi.org/10.1002/eji.20104042810.1002/eji.201040428 ↗
56. F. Castellano, V. Molinier-Frenkel, (2017) An overview of l-amino acid oxidase functions from bacteria to mammals: focus on the immunoregulatory phenylalanine oxidase IL4I1. Molecules 22 .https://doi.org/10.3390/molecules2212215110.3390/molecules22122151 ↗
57. Li J, Zheng C, Mai Q, Huang X, Pan W, Lu J, Chen Z, Zhang S, Zhang C, Huang H, Chen Y, Guo H, Wu Z, Deng C, Jiang Y, Li B, Liu J, Yao S, Pan C (2023) Tyrosine catabolism enhances genotoxic chemotherapy by suppressing translesion DNA synthesis in epithelial ovarian cancer. Cell Metab 35:2044–2059. https://doi.org/10.1016/j.cmet.2023.10.00210.1016/j.cmet.2023.10.002 ↗
58. Cheng L, Wang X, Liu A, Zhu Y, Cheng H, Yu J, Gong L, Liu H, Shen G, Liu L (2024) Phenylalanine deprivation inhibits multiple myeloma progression by perturbing endoplasmic reticulum homeostasis. Acta Pharm Sin B 14:3493–3512. https://doi.org/10.1016/j.apsb.2024.04.02110.1016/j.apsb.2024.04.021 ↗
59. Zhao LP, Zheng RR, Huang JQ, Chen XY, Deng FA, Liu YB, Huang CY, Yu XY, Cheng H, Li SY (2020) Self-delivery photo-immune stimulators for photodynamic sensitized tumor immunotherapy. ACS Nano 14:17100–17113. https://doi.org/10.1021/acsnano.0c0676510.1021/acsnano.0c06765 ↗
60. Zhang C, Zeng Z, Cui D, He S, Jiang Y, Li J, Huang J, Pu K (2021) Semiconducting polymer nano-PROTACs for activatable photo-immunometabolic cancer therapy. Nat Commun 12:2934. https://doi.org/10.1038/s41467-021-23194-w10.1038/s41467-021-23194-w ↗
61. Zhang J, Sun X, Zhao X, Liu L, Cheng X, Yang C, Hu H, Qiao M, Chen D, Zhao X (2022) Watson-crick base pairing-inspired laser/gsh activatable mirna-coordination polymer nanoplexes for combined cancer chemo-immuno-photothermal therapy. ACS Appl Mater Interfaces 14:20762–20777. https://doi.org/10.1021/acsami.2c0352310.1021/acsami.2c03523 ↗
62. Hu C, Liu Y, Cao W, Li N, Gao S, Wang Z, Gu F (2024) Efficacy and mechanism of a biomimetic nanosystem carrying doxorubicin and an ido inhibitor for treatment of advanced triple-negative breast cancer. Int J Nanomed 19:507–526. https://doi.org/10.2147/IJN.S44033210.2147/IJN.S440332 ↗
63. Zhai Q, Chen Y, Xu J, Huang Y, Sun J, Liu Y, Zhang X, Li S, Tang S (2017) Lymphoma immunochemotherapy: targeted delivery of doxorubicin via a dual functional nanocarrier. Mol Pharm 14:3888–3895. https://doi.org/10.1021/acs.molpharmaceut.7b0060610.1021/acs.molpharmaceut.7b00606 ↗
64. Kim M, Lee JS, Kim W, Lee JH, Jun BH, Kim KS, Kim DE (2022) Aptamer-conjugated nano-liposome for immunogenic chemotherapy with reversal of immunosuppression. J Control Release 348:893–910. https://doi.org/10.1016/j.jconrel.2022.06.03910.1016/j.jconrel.2022.06.039 ↗
65. Hanurry EY, Birhan YS, Darge HF, Mekonnen TW, Arunagiri V, Chou HY, Cheng CC, Lai JY, Tsai HC (2022) PAMAM dendritic nanoparticle-incorporated hydrogel to enhance the immunogenic cell death and immune response of immunochemotherapy. ACS Biomater Sci Eng 8:2403–2418. https://doi.org/10.1021/acsbiomaterials.2c0017110.1021/acsbiomaterials.2c00171 ↗
66. Wang B, Chen J, Caserto JS, Wang X, Ma M (2022) An in situ hydrogel-mediated chemo-immunometabolic cancer therapy. Nat Commun 13:3821. https://doi.org/10.1038/s41467-022-31579-810.1038/s41467-022-31579-8 ↗
67. Lu J, Liu X, Liao YP, Salazar F, Sun B, Jiang W, Chang CH, Jiang J, Wang X, Wu AM, Meng H, Nel AE (2017) Nano-enabled pancreas cancer immunotherapy using immunogenic cell death and reversing immunosuppression. Nat Commun 8:1811. https://doi.org/10.1038/s41467-017-01651-910.1038/s41467-017-01651-9 ↗
68. Khoshkhabar R, Yazdani M, Hoda AS, Saberi Z, Arabi L, Reza JM (2024) Chemo-immunotherapy by nanoliposomal epacadostat and docetaxel combination to IDO1 inhibition and tumor microenvironment suppression. Int Immunopharmacol 137:112437. https://doi.org/10.1016/j.intimp.2024.11243710.1016/j.intimp.2024.112437 ↗
69. Zhu Y, Yang Z, Dong Z, Gong Y, Hao Y, Tian L, Yang X, Liu Z, Feng L (2020) CaCO(3)-Assisted preparation of pH-responsive immune-modulating nanoparticles for augmented chemo-immunotherapy. Nano-Micro Lett 13:29. https://doi.org/10.1007/s40820-020-00549-410.1007/s40820-020-00549-4 ↗
70. Wang Z, Li W, Jiang Y, Tran TB, Chung J, Kim M, Scott AJ, Lu J (2024) Camptothesome-based combination nanotherapeutic regimen for improved colorectal cancer immunochemotherapy. Biomaterials 306:122477. https://doi.org/10.1016/j.biomaterials.2024.12247710.1016/j.biomaterials.2024.122477 ↗
71. Zhao L, Zheng R, Liu L, Chen X, Guan R, Yang N, Chen A, Yu X, Cheng H, Li S (2021) Self-delivery oxidative stress amplifier for chemotherapy sensitized immunotherapy. Biomaterials 275:120970. https://doi.org/10.1016/j.biomaterials.2021.12097010.1016/j.biomaterials.2021.120970 ↗
72. Tang K, Wu Y, Song Y, Yu B (2021) Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors in clinical trials for cancer immunotherapy. J Hematol Oncol 14:68. https://doi.org/10.1186/s13045-021-01080-810.1186/s13045-021-01080-8 ↗
73. Yao Y, Liang H, Fang X, Zhang S, Xing Z, Shi L, Kuang C, Seliger B, Yang Q (2021) What is the prospect of indoleamine 2,3-dioxygenase 1 inhibition in cancer? Extrapolation from the past. J Exp Clin Cancer Res 40:60. https://doi.org/10.1186/s13046-021-01847-410.1186/s13046-021-01847-4 ↗
74. Muller AJ, Manfredi MG, Zakharia Y, Prendergast GC (2019) Inhibiting IDO pathways to treat cancer: lessons from the ECHO-301 trial and beyond. Semin Immunopathol 41:41–48. https://doi.org/10.1007/s00281-018-0702-010.1007/s00281-018-0702-0 ↗
75. Badawy AA, Guillemin G (2019) The plasma [Kynurenine]/[Tryptophan] ratio and indoleamine 2,3-dioxygenase: Time for appraisal. Int J Trypotophan Res 12:519664178. https://doi.org/10.1177/117864691986897810.1177/1178646919868978 ↗
76. Kenski JCN, Huang X, Vredevoogd DW, de Bruijn B, Traets JJH, Ibanez-Molero S, Schieven SM, van Vliet A, Krijgsman O, Kuilman T, Pozniak J, Loayza-Puch F, Terry AM, Muller J, Logtenberg MEW, de Bruijn M, Levy P, Korner P, Goding CR, Schumacher TN, Marine J, Agami R, Peeper DS (2023) An adverse tumor-protective effect of IDO1 inhibition. Cell Rep Med 4:100941. https://doi.org/10.1016/j.xcrm.2023.10094110.1016/j.xcrm.2023.100941 ↗
77. Wang C, Dong Z, Hao Y, Zhu Y, Ni J, Li Q, Liu B, Han Y, Yang Z, Wan J, Yang K, Liu Z, Feng L (2022) Coordination polymer-coated CaCO(3) reinforces radiotherapy by Reprogramming the Immunosuppressive Metabolic Microenvironment. Adv Mater 34:e2106520. https://doi.org/10.1002/adma.20210652010.1002/adma.202106520 ↗
78. Li C, You X, Xu X, Wu B, Liu Y, Tong T, Chen J, Li Y, Dai C, Ye Z, Tian X, Wei Y, Hao Z, Jiang L, Wu J, Zhao M (2022) A metabolic reprogramming amino acid polymer as an immunosurveillance activator and leukemia targeting drug carrier for T-Cell Acute Lymphoblastic Leukemia. Adv Sci 9:e2104134. https://doi.org/10.1002/advs.20210413410.1002/advs.202104134 ↗
79. Chen Y, Wang C, Wu Y, Wang Y, Meng Y, Wu F, Zhang H, Cheng YY, Jiang X, Shi J, Li H, Zhao P, Wu J, Zheng B, Jin D, Bu W (2024) Nutrient-delivery and metabolism reactivation therapy for melanoma. Nat Nanotechnol. https://doi.org/10.1038/s41565-024-01690-610.1038/s41565-024-01690-6 ↗
80. Wang Z, Li B, Li S, Lin W, Wang Z, Wang S, Chen W, Shi W, Chen T, Zhou H, Yinwang E, Zhang W, Mou H, Chai X, Zhang J, Lu Z, Ye Z (2022) Metabolic control of CD47 expression through LAT2-mediated amino acid uptake promotes tumor immune evasion. Nat Commun 13:6308. https://doi.org/10.1038/s41467-022-34064-410.1038/s41467-022-34064-4 ↗
81. Gu Z, Liu Y, Cai F, Patrick M, Zmajkovic J, Cao H, Zhang Y, Tasdogan A, Chen M, Qi L, Liu X, Li K, Lyu J, Dickerson KE, Chen W, Ni M, Merritt ME, Morrison SJ, Skoda RC, DeBerardinis RJ, Xu J (2019) Loss of EZH2 reprograms BCAA metabolism to drive leukemic transformation. Cancer Discov 9:1228–1247. https://doi.org/10.1158/2159-8290.CD-19-015210.1158/2159-8290.CD-19-0152 ↗
82. Ericksen RE, Lim SL, McDonnell E, Shuen WH, Vadiveloo M, White PJ, Ding Z, Kwok R, Lee P, Radda GK, Toh HC, Hirschey MD, Han W (2019) Loss of BCAA catabolism during carcinogenesis enhances mTORC1 activity and promotes tumor development and progression. Cell Metab 29:1151–1165. https://doi.org/10.1016/j.cmet.2018.12.02010.1016/j.cmet.2018.12.020 ↗
83. Qu YY, Zhao R, Zhang HL, Zhou Q, Xu FJ, Zhang X, Xu WH, Shao N, Zhou SX, Dai B, Zhu Y, Shi GH, Shen YJ, Zhu YP, Han CT, Chang K, Lin Y, Zang WD, Xu W, Ye DW, Zhao SM, Zhao JY (2020) Inactivation of the AMPK-GATA3-ECHS1 pathway induces fatty acid synthesis that promotes clear cell renal cell carcinoma growth. Cancer Res 80:319–333. https://doi.org/10.1158/0008-5472.CAN-19-102310.1158/0008-5472.CAN-19-1023 ↗
84. Zhang L, Han J (2017) Branched-chain amino acid transaminase 1 (BCAT1) promotes the growth of breast cancer cells through improving mTOR-mediated mitochondrial biogenesis and function. Biochem Biophys Res Commun 486:224–231. https://doi.org/10.1016/j.bbrc.2017.02.10110.1016/j.bbrc.2017.02.101 ↗
85. Mayers JR, Torrence ME, Danai LV, Papagiannakopoulos T, Davidson SM, Bauer MR, Lau AN, Ji BW, Dixit PD, Hosios AM, Muir A, Chin CR, Freinkman E, Jacks T, Wolpin BM, Vitkup D, Vander HM (2016) Tissue of origin dictates branched-chain amino acid metabolism in mutant Kras-driven cancers. Science 353:1161–1165. https://doi.org/10.1126/science.aaf517110.1126/science.aaf5171 ↗
86. Wang ZQ, Faddaoui A, Bachvarova M, Plante M, Gregoire J, Renaud MC, Sebastianelli A, Guillemette C, Gobeil S, Macdonald E, Vanderhyden B, Bachvarov D (2015) BCAT1 expression associates with ovarian cancer progression: possible implications in altered disease metabolism. Oncotarget 6:31522–31543. https://doi.org/10.18632/oncotarget.515910.18632/oncotarget.5159 ↗
87. Tonjes M, Barbus S, Park YJ, Wang W, Schlotter M, Lindroth AM, Pleier SV, Bai A, Karra D, Piro RM, Felsberg J, Addington A, Lemke D, Weibrecht I, Hovestadt V, Rolli CG, Campos B, Turcan S, Sturm D, Witt H, Chan TA, Herold-Mende C, Kemkemer R, Konig R, Schmidt K, Hull WE, Pfister SM, Jugold M, Hutson SM, Plass C, Okun JG, Reifenberger G, Lichter P, Radlwimmer B (2013) BCAT1 promotes cell proliferation through amino acid catabolism in gliomas carrying wild-type IDH1. Nat Med 19:901–908. https://doi.org/10.1038/nm.321710.1038/nm.3217 ↗
88. Peng H, Wang Y, Luo W (2020) Multifaceted role of branched-chain amino acid metabolism in cancer. Oncogene 39:6747–6756. https://doi.org/10.1038/s41388-020-01480-z10.1038/s41388-020-01480-z ↗
89. Yao CC, Sun RM, Yang Y, Zhou HY, Meng ZW, Chi R, Xia LL, Ji P, Chen YY, Zhang GQ, Sun HP, Lu S, Yang C, Wang Y (2023) Accumulation of branched-chain amino acids reprograms glucose metabolism in CD8(+) T cells with enhanced effector function and anti-tumor response. Cell Rep 42:112186. https://doi.org/10.1016/j.celrep.2023.11218610.1016/j.celrep.2023.112186 ↗
90. Wu Y, Ma J, Yang X, Nan F, Zhang T, Ji S, Rao D, Feng H, Gao K, Gu X, Jiang S, Song G, Pan J, Zhang M, Xu Y, Zhang S, Fan Y, Wang X, Zhou J, Yang L, Fan J, Zhang X, Gao Q (2024) Neutrophil profiling illuminates anti-tumor antigen-presenting potency. Cell 187:1422–1439. https://doi.org/10.1016/j.cell.2024.02.00510.1016/j.cell.2024.02.005 ↗
91. Takami T, Yamasaki T, Saeki I, Matsumoto T, Suehiro Y, Sakaida I (2016) Supportive therapies for prevention of hepatocellular carcinoma recurrence and preservation of liver function. World J Gastroenterol 22:7252–7263. https://doi.org/10.3748/wjg.v22.i32.725210.3748/wjg.v22.i32.7252 ↗
92. Nojiri S, Fujiwara K, Shinkai N, Iio E, Joh T (2017) Effects of branched-chain amino acid supplementation after radiofrequency ablation for hepatocellular carcinoma: A randomized trial. Nutrition 33:20–27. https://doi.org/10.1016/j.nut.2016.07.01310.1016/j.nut.2016.07.013 ↗
93. Ikeda K, Kinoshita M, Kayama H, Nagamori S, Kongpracha P, Umemoto E, Okumura R, Kurakawa T, Murakami M, Mikami N, Shintani Y, Ueno S, Andou A, Ito M, Tsumura H, Yasutomo K, Ozono K, Takashima S, Sakaguchi S, Kanai Y, Takeda K (2017) Slc3a2 mediates branched-chain amino-acid-dependent maintenance of regulatory T cells. Cell Rep 21:1824–1838. https://doi.org/10.1016/j.celrep.2017.10.08210.1016/j.celrep.2017.10.082 ↗
94. Xu X, Wang J, Tong T, Zhang W, Wang J, Ma W, Wang S, Zhou D, Wu J, Jiang L, Zhao M (2022) A self-assembled leucine polymer sensitizes leukemic stem cells to chemotherapy by inhibiting autophagy in acute myeloid leukemia. Haematologica 107:2344–2355. https://doi.org/10.3324/haematol.2021.28029010.3324/haematol.2021.280290 ↗
95. Mato JM, Martinez-Chantar ML, Lu SC (2008) Methionine metabolism and liver disease. Annu Rev Nutr 28:273–293. https://doi.org/10.1146/annurev.nutr.28.061807.15543810.1146/annurev.nutr.28.061807.155438 ↗
96. Xu Q, Li Y, Gao X, Kang K, Williams JG, Tong L, Liu J, Ji M, Deterding LJ, Tong X, Locasale JW, Li L, Shats I, Li X (2020) HNF4alpha regulates sulfur amino acid metabolism and confers sensitivity to methionine restriction in liver cancer. Nat Commun 11:3978. https://doi.org/10.1038/s41467-020-17818-w10.1038/s41467-020-17818-w ↗
97. Wang Z, Yip LY, Lee J, Wu Z, Chew HY, Chong P, Teo CC, Ang HY, Peh K, Yuan J, Ma S, Choo L, Basri N, Jiang X, Yu Q, Hillmer AM, Lim WT, Lim T, Takano A, Tan EH, Tan D, Ho YS, Lim B, Tam WL (2019) Methionine is a metabolic dependency of tumor-initiating cells. Nat Med 25:825–837. https://doi.org/10.1038/s41591-019-0423-510.1038/s41591-019-0423-5 ↗
98. Roy DG, Chen J, Mamane V, Ma EH, Muhire BM, Sheldon RD, Shorstova T, Koning R, Johnson RM, Esaulova E, Williams KS, Hayes S, Steadman M, Samborska B, Swain A, Daigneault A, Chubukov V, Roddy TP, Foulkes W, Pospisilik JA, Bourgeois-Daigneault MC, Artyomov MN, Witcher M, Krawczyk CM, Larochelle C, Jones RG (2020) Methionine metabolism shapes t helper cell responses through regulation of epigenetic reprogramming. Cell Metab 31:250–266. https://doi.org/10.1016/j.cmet.2020.01.00610.1016/j.cmet.2020.01.006 ↗
99. Li T, Tan YT, Chen YX, Zheng XJ, Wang W, Liao K, Mo HY, Lin J, Yang W, Piao HL, Xu RH, Ju HQ (2023) Methionine deficiency facilitates antitumour immunity by altering m(6)A methylation of immune checkpoint transcripts. Gut 72:501–511. https://doi.org/10.1136/gutjnl-2022-32692810.1136/gutjnl-2022-326928 ↗
100. Bian Y, Li W, Kremer DM, Sajjakulnukit P, Li S, Crespo J, Nwosu ZC, Zhang L, Czerwonka A, Pawlowska A, Xia H, Li J, Liao P, Yu J, Vatan L, Szeliga W, Wei S, Grove S, Liu JR, McLean K, Cieslik M, Chinnaiyan AM, Zgodzinski W, Wallner G, Wertel I, Okla K, Kryczek I, Lyssiotis CA, Zou W (2020) Cancer SLC43A2 alters T cell methionine metabolism and histone methylation. Nature 585:277–282. https://doi.org/10.1038/s41586-020-2682-110.1038/s41586-020-2682-1 ↗